LIGANDAL | REGENERATIVE PEPTIDES
  • OVERVIEW
  • COVID-19
  • OUR SCIENCE
  • NEWSROOM
  • BOARD OF DIRECTORS
  • ADVISORY BOARD
  • CONTACT US

LIGANDAL

​Ligandal is a regenerative medicine and pandemic defense biotechnology company. Our current lead candidate, SARS-BLOCK™, is designed as an "antidote-vaccine" against the virus that causes COVID-19.
     
​We use supercomputing and AI to develop next-generation medicine, bringing you nearly a decade of experience in developing peptide-based technologies for gene therapy, gene editing, regenerative medicine, immunotherapy, and advanced antidote-vaccine technologies.
LIGANDAL COVID-19 RESOURCE CENTER

SEE OUR PUBLICATION: PEPTIDE ANTIDOTES TO SARS-COV-2 (COVID-19)
Picture

CHEMICAL & ENGINEERING NEWS (ACS PUBLICATIONS)
C&EN's 2019 10 Start-Ups to Watch


"You can have the fanciest ideas and molecules, but if you can't get them into the cell, they are of no use.”

- Matthew Porteus, co-founder, crispr therapeutics

peptide NANOROBOTS.
PANDEMIC DEFENSE TECHNOLOGY.
REGENERATIVE MEDICINE.

delivery

We deliver antidotes, vaccines, gene therapies, gene editing, and more.

cell specificity

We can target any cellular receptor.

computational modeling

We predict how our constructs will behave, then we make them.
DISCOVER OUR PROCESS & SCIENCE

THE NEXT GENERATION OF MEDICINE IS HERE.

Ⓒ 2019 Ligandal Inc. All rights reserved.
  • OVERVIEW
  • COVID-19
  • OUR SCIENCE
  • NEWSROOM
  • BOARD OF DIRECTORS
  • ADVISORY BOARD
  • CONTACT US